Spyre Therapeutics develops antibody drugs for inflammatory bowel disease and rheumatic conditions. It last closed at $93.47 on Nov 20, down 4.26% on the day. The next earnings report for SYRE is expected around Thu, Feb 18, 2027, after the close. Over its last 8 reports the stock moved an average of 6.2% the session after earnings. Over the last 12 months SYRE insiders bought $0 of stock on the open market and sold $441.9M, according to SEC Form 4 filings.
AI Auto Pilots
Is SYRE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SYRE.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on SYREStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
SYRE · as of the Nov 20 close · updated each morning
Moving sideways
The stock sits between its 20 and 50 day averages. It is 16% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 46). The nearest support is the swing low (Nov 17) at $92.92, and the nearest resistance the swing high (Oct 21) at $95.17.
Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 6.1%/day
Key levels
$110.6452 week high+18.4%
$99.7220 day average+6.7%
$97.61Pivot R1+4.4%
$95.42Pivot+2.1%
$95.19100 day average+1.8%
$95.17Swing high (Oct 21)+1.8%
$93.47Last close
$92.92Swing low (Nov 17)−0.6%
$92.2850 day average−1.3%
$91.27Pivot S1−2.4%
$78.28200 day average−16.3%
$23.0152 week low−75.4%
Indicators
RSI (14)
46.18
Middle of its range
Neutral
MACD
1.70
Below its signal line
Bearish
Stochastic
26.6
Middle of its range
Neutral
ADX (14)
14.8
No clear trend
Williams %R
-96.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-85.9
Oversold below −100, overbought above 100
Neutral
Rate of change
−10.0%
Change over 10 sessions
Bearish
ATR (14)
$5.72
Typical daily range, 6.1% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumNeutral
StretchNormal
VolatilityNormal, 11.7%/day
Key levels
$110.6452 week high+18.4%
$99.7220 day average+6.7%
$97.61Pivot R1+4.4%
$95.42Pivot+2.1%
$95.19100 day average+1.8%
$95.17Swing high (Oct 21)+1.8%
$93.47Last close
$92.92Swing low (Nov 17)−0.6%
$92.2850 day average−1.3%
$91.27Pivot S1−2.4%
$78.28200 day average−16.3%
$23.0152 week low−75.4%
Indicators
RSI (14)
54.87
Middle of its range
Neutral
MACD
6.52
Below its signal line
Bearish
Stochastic
70.2
Middle of its range
Neutral
ADX (14)
35.6
Trending up
Williams %R
-50.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
28.2
Oversold below −100, overbought above 100
Neutral
Rate of change
+3.2%
Change over 10 sessions
Bullish
ATR (14)
$10.96
Typical daily range, 11.7% of price
MA 10Above
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for SYRE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how SYRE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow SYRE usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for SYREHow many large options trades hit SYRE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in SYRE in the last 90 days.
From SEC Form 4 filings by SYRE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SYRE is in one of them and how their past SYRE trades turned out.
Spyre Therapeutics is a biotechnology company based in Waltham, Massachusetts, that develops antibody medicines. Its drug candidates are designed to act on the immune system and to last longer between doses, with the aim of treating inflammatory bowel disease, which includes ulcerative colitis and Crohn's disease. The company is also studying its anti-TL1A antibody for rheumatic conditions such as rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Its target patients are people living with these chronic immune conditions, and its products are still in development rather than on the market.